Leigh Marcus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leigh Marcus has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- AeRang Kim
Division of Oncology, Center for Cancer and Blood Disorders, Children’s National Hospital , Washington, District of Columbia
1 shared publication Andrew Fisher
Standards and Compliance Function Medicines and Healthcare Products Regulatory Agency (MHRA) London UK
1 shared publication- Anjali Srivastava
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi 110029, India
1 shared publication - Anne Goodwin
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, United States
1 shared publication - Brigitte C. Widemann
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland
1 shared publication - Carmen C. Brewer
Auditory and Vestibular Clinical Research Section , Neurotology Branch , National Institute on Deafness and Other Communication Disorders (NIDCD) , National Institutes of Health , Bethesda , Maryland , USA , nih.gov
1 shared publication
Latest Publications
- 5 November 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (5) , 1172-1178
Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
As clinical trial design and conduct continue to evolve with innovative approaches, new technologies, and emerging data sources, regulatory frameworks are undergoing significant updates to align with these advancements. This article explores recent revisions to the International Council for Harmonization (ICH) Guideline for Good Clinical Practice (GCP) E6(R3) and the regulatory perspectives on adopting a risk‐proportionate approach to trial design and conduct. Drawing from insights shared at the FDA‐MHRA‐HC 2024 Joint GCP Symposium, this article highlights the key themes shaping the future of clinical trials, including quality‐by‐design (QbD), risk proportionality, and cross‐regulatory collaboration. Additionally, this article addresses the impact of the COVID‐19 pandemic in accelerating trial innovations, such as the use of decentralized trial elements and digital health technologies (DHTs), while also emphasizing the need for regulatory flexibility to accelerate their adoption. Regulatory agencies, such as the US‐FDA, MHRA‐UK, and Health Canada, have issued guidance to promote clinical trial flexibilities and proportionate, risk‐based approaches, ensuring the protection of participant rights, safety, and well‐being and overall reliability of trial results. These updates advocate for proportionate approaches to trial oversight, which allow for innovation while safeguarding the trial's critical to quality factors. As regulators continue to refine their practices and enhance collaboration, the integration of QbD and risk proportionality into clinical trials and cross‐regulatory collaboration will ultimately drive more efficient, participant‐centered trials and improve the global clinical research landscape.
- 5 November 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (5) , 1172-1178
Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
As clinical trial design and conduct continue to evolve with innovative approaches, new technologies, and emerging data sources, regulatory frameworks are undergoing significant updates to align with these advancements. This article explores recent revisions to the International Council for Harmonization (ICH) Guideline for Good Clinical Practice (GCP) E6(R3) and the regulatory perspectives on adopting a risk‐proportionate approach to trial design and conduct. Drawing from insights shared at the FDA‐MHRA‐HC 2024 Joint GCP Symposium, this article highlights the key themes shaping the future of clinical trials, including quality‐by‐design (QbD), risk proportionality, and cross‐regulatory collaboration. Additionally, this article addresses the impact of the COVID‐19 pandemic in accelerating trial innovations, such as the use of decentralized trial elements and digital health technologies (DHTs), while also emphasizing the need for regulatory flexibility to accelerate their adoption. Regulatory agencies, such as the US‐FDA, MHRA‐UK, and Health Canada, have issued guidance to promote clinical trial flexibilities and proportionate, risk‐based approaches, ensuring the protection of participant rights, safety, and well‐being and overall reliability of trial results. These updates advocate for proportionate approaches to trial oversight, which allow for innovation while safeguarding the trial's critical to quality factors. As regulators continue to refine their practices and enhance collaboration, the integration of QbD and risk proportionality into clinical trials and cross‐regulatory collaboration will ultimately drive more efficient, participant‐centered trials and improve the global clinical research landscape.
- 7 October 2022
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (5) , 838-842
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Approval was based on FIGHT-202 (NCT02924376), a multicenter open-label single-arm trial. Efficacy was based on 107 patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least one prior therapy and had an FGFR2 gene fusion or rearrangement. Patients received pemigatinib, 13.5 mg orally, once daily for 14 consecutive days, followed by 7 days off therapy. Safety was based on a total of 466 patients, 146 of whom had cholangiocarcinoma and received the recommended dose. Efficacy endpoints were overall response rate (ORR) and duration of response (DOR) determined by an independent review committee using RECIST 1.1. ORR was 36% (95% confidence interval: 27–45). Median DOR was 9.1 months. The most common adverse reactions were hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin. Ocular toxicity and hyperphosphatemia are important risks of pemigatinib. The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy in 21-day cycles. FDA also approved the FoundationOne CDX (Foundation Medicine, Inc.) as a companion diagnostic for patient selection.
- 7 October 2022
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (5) , 838-842
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Approval was based on FIGHT-202 (NCT02924376), a multicenter open-label single-arm trial. Efficacy was based on 107 patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least one prior therapy and had an FGFR2 gene fusion or rearrangement. Patients received pemigatinib, 13.5 mg orally, once daily for 14 consecutive days, followed by 7 days off therapy. Safety was based on a total of 466 patients, 146 of whom had cholangiocarcinoma and received the recommended dose. Efficacy endpoints were overall response rate (ORR) and duration of response (DOR) determined by an independent review committee using RECIST 1.1. ORR was 36% (95% confidence interval: 27–45). Median DOR was 9.1 months. The most common adverse reactions were hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin. Ocular toxicity and hyperphosphatemia are important risks of pemigatinib. The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy in 21-day cycles. FDA also approved the FoundationOne CDX (Foundation Medicine, Inc.) as a companion diagnostic for patient selection.
- Open Access
- 3 January 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (4) , 603-610
Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors
Background Based on pre‐clinical and clinical activity in adult refractory tumors, and absence of significant neuro‐, nephro‐, or oto‐toxicity, we conducted a pediatric phase 1 trial to determine the toxicities, maximum tolerated dose (MTD), and pharmacokinetics of satraplatin, an oral platinum analogue, in children and young adults with refractory solid tumors. Procedure Satraplatin was administered orally once daily on days 1–5 of a 28‐day cycle at dose level (DL) 1 (60 mg/m2/dose), and DL2 (80 mg/m2/dose). Toxicities, responses, satraplatin pharmacokinetics, and pharmacogenomic expression of specific DNA repair genes were evaluated. Results Nine patients received 1–15 cycles (median = 2). The MTD was exceeded at DL2 with delayed prolonged myelosuppression as dose‐limiting toxicity (DLT) in 2/4 patients. At DL1, 0/5 patients had DLTs. Common non‐DLTs included myelosuppression, gastrointestinal toxicities, fatigue, headache, liver enzyme elevation, and electrolyte abnormalities. No significant neuro‐, nephro‐, or oto‐toxicity was observed. No objective responses were observed but 2 patients experienced prolonged disease stabilization (6–15 cycles). Satraplatin exposure (day 1 plasma ultrafiltrate area under the curve) was similar at DL1 and DL2. A strong correlation between estimated creatinine clearance and satraplatin pharmacokinetic parameters (clearance, area under the curve, and peak concentration) was observed. Conclusions The MTD of oral satraplatin in children with solid tumors was 60 mg/m2/dose daily ×5 days every 28 days, which is lower than the adult recommended dose of 80–120 mg/m2/dose. The toxicity profile was similar to adults and delayed myelosuppression was the DLT. No significant neuro‐, nephro‐ or oto‐toxicities were observed. Pediatr Blood Cancer 2015;62:603–610.
- 3 January 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (4) , 603-610
Open AccessPhase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors
Background Based on pre‐clinical and clinical activity in adult refractory tumors, and absence of significant neuro‐, nephro‐, or oto‐toxicity, we conducted a pediatric phase 1 trial to determine the toxicities, maximum tolerated dose (MTD), and pharmacokinetics of satraplatin, an oral platinum analogue, in children and young adults with refractory solid tumors. Procedure Satraplatin was administered orally once daily on days 1–5 of a 28‐day cycle at dose level (DL) 1 (60 mg/m2/dose), and DL2 (80 mg/m2/dose). Toxicities, responses, satraplatin pharmacokinetics, and pharmacogenomic expression of specific DNA repair genes were evaluated. Results Nine patients received 1–15 cycles (median = 2). The MTD was exceeded at DL2 with delayed prolonged myelosuppression as dose‐limiting toxicity (DLT) in 2/4 patients. At DL1, 0/5 patients had DLTs. Common non‐DLTs included myelosuppression, gastrointestinal toxicities, fatigue, headache, liver enzyme elevation, and electrolyte abnormalities. No significant neuro‐, nephro‐, or oto‐toxicity was observed. No objective responses were observed but 2 patients experienced prolonged disease stabilization (6–15 cycles). Satraplatin exposure (day 1 plasma ultrafiltrate area under the curve) was similar at DL1 and DL2. A strong correlation between estimated creatinine clearance and satraplatin pharmacokinetic parameters (clearance, area under the curve, and peak concentration) was observed. Conclusions The MTD of oral satraplatin in children with solid tumors was 60 mg/m2/dose daily ×5 days every 28 days, which is lower than the adult recommended dose of 80–120 mg/m2/dose. The toxicity profile was similar to adults and delayed myelosuppression was the DLT. No significant neuro‐, nephro‐ or oto‐toxicities were observed. Pediatr Blood Cancer 2015;62:603–610.